LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
- Your personalised programme is built around medical care, not willpower.
- No generic diets. No guesswork.
- Just science-backed results and expert support.
Find out if you’re eligible
Tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for weight management) is a dual GIP/GLP-1 receptor agonist licensed in the UK for weight management in adults with obesity or overweight with weight-related comorbidities. The mounjaro maintenance dose for weight loss typically ranges from 5 mg to 15 mg once weekly, depending on individual response and tolerability. Reaching and sustaining an appropriate maintenance dose is essential for long-term weight management success. This article explains how maintenance dosing works, the titration process, monitoring requirements, and strategies for managing side effects whilst on treatment.
Quick Answer: The mounjaro maintenance dose for weight loss is typically 10 mg or 15 mg once weekly, though some patients remain on 5 mg if they achieve satisfactory results.
Tirzepatide is a prescription medicine licensed in the UK for weight management in adults with obesity or those who are overweight with at least one weight-related comorbidity. It is marketed as Zepbound for weight management and as Mounjaro for type 2 diabetes treatment. Tirzepatide represents a novel class of medication known as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This dual mechanism distinguishes it from other weight loss medications currently available.
The medication works through several complementary pathways to promote weight loss. By activating GLP-1 receptors, tirzepatide slows gastric emptying, which helps you feel fuller for longer after eating. It also acts on appetite centres in the brain to reduce hunger and food cravings. The GIP component enhances these effects, though its precise contribution to weight management is not fully elucidated. Together, these mechanisms lead to reduced calorie intake and sustained weight loss over time.
Tirzepatide is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. Clinical trials (SURMOUNT-1 and SURMOUNT-2) have demonstrated significant weight loss outcomes, with participants losing an average of 15-20% of their initial body weight over 72 weeks when combined with lifestyle modifications, with higher doses generally producing greater effects. The Medicines and Healthcare products Regulatory Agency (MHRA) approved tirzepatide for weight management in the UK, and NICE guidance (TA906) supports its use for adults with specific BMI thresholds and weight-related conditions, within specialist weight management services.
It is essential to understand that tirzepatide is not a standalone solution. The medication works most effectively when combined with a reduced-calorie diet and increased physical activity. Healthcare professionals will assess your suitability for treatment based on your body mass index (BMI), existing health conditions, and previous weight loss attempts.
Tirzepatide should not be used during pregnancy or breastfeeding and is not recommended for people under 18 years of age. Caution is advised in people with severe gastrointestinal disease, gastroparesis, or diabetic retinopathy. The medication should only be initiated and monitored under medical supervision to ensure safety and effectiveness.
LOSE WEIGHT WITH MEDICAL SUPPORT — BUILT FOR MEN
Find out if you’re eligible
The maintenance dose of tirzepatide refers to the target therapeutic dose that you continue taking long-term to sustain weight loss and metabolic benefits. For weight management, the licensed maintenance doses in the UK are typically 10 mg or 15 mg once weekly, depending on individual response and tolerability. According to the Summary of Product Characteristics (SmPC), some patients may remain on a lower dose of 5 mg if they achieve satisfactory results with acceptable side effects or if higher doses are not tolerated.
Unlike the initial titration phase where doses are gradually increased, the maintenance phase represents a stable dosing regimen. The purpose of reaching a maintenance dose is twofold: to maximise weight loss benefits whilst minimising gastrointestinal side effects that can occur with rapid dose escalation. Clinical evidence suggests that higher maintenance doses (10-15 mg) generally produce greater weight loss compared to lower doses, though individual responses vary considerably.
Determining your optimal maintenance dose involves collaboration between you and your healthcare provider. Factors considered include:
Weight loss progress: Whether you are achieving clinically meaningful weight loss (typically ≥5% of initial body weight)
Tolerability: How well you manage side effects at each dose level
Metabolic improvements: Changes in blood pressure, blood glucose, and lipid profiles
Individual treatment goals: Your target weight and health objectives
It is important to recognise that the maintenance dose is not necessarily the highest dose. Some individuals achieve excellent results on 5 mg weekly and may not require further escalation. Your prescriber will review your progress regularly—typically every 3-6 months—to assess whether your current maintenance dose remains appropriate or requires adjustment. The optimal approach is personalised dosing based on your individual response and tolerability, as recommended in the UK product information.
Reaching your maintenance dose involves a structured dose escalation schedule designed to improve gastrointestinal tolerability. The standard titration protocol for tirzepatide begins with 2.5 mg once weekly for the first four weeks. This starting dose allows your body to adapt to the medication's effects on gastric emptying and appetite regulation.
The typical escalation pathway proceeds as follows:
Weeks 1-4: 2.5 mg once weekly
Weeks 5-8: 5 mg once weekly
Weeks 9-12: 7.5 mg once weekly
Weeks 13-16: 10 mg once weekly
Weeks 17-20: 12.5 mg once weekly (if required)
Week 21 onwards: 15 mg once weekly (if required)
Each dose increase occurs at four-week intervals, though your healthcare provider may adjust this timeline based on your individual response and side effect profile. If you experience significant gastrointestinal symptoms at any stage, your doctor may recommend staying at your current dose for an additional four weeks before attempting further escalation, or they may determine that your current dose is your optimal maintenance level.
Maintaining your target dose requires consistency and adherence to your injection schedule. Administer tirzepatide on the same day each week, though the time of day can vary. If needed, you can change your weekly dosing day, provided at least 3 days (72 hours) have elapsed between doses. If you miss a dose and it has been less than 4 days since your scheduled injection, take it as soon as possible. If more than 4 days have passed, skip the missed dose and resume your regular schedule.
Regular follow-up appointments are essential during maintenance treatment. Your healthcare team will monitor:
Weight loss trajectory and body composition changes
Blood pressure and cardiovascular parameters
Metabolic markers (HbA1c if you have diabetes, lipid profile)
Renal function, particularly if you experience dehydration from gastrointestinal side effects
Gallbladder symptoms
Diabetic retinopathy monitoring if you have diabetes
Tolerability and quality of life
Adherence to lifestyle modifications
Your clinician will periodically reassess the benefits and risks of continued treatment based on your clinical response, tolerability, and in accordance with local and NICE guidance.
Gastrointestinal side effects are the most commonly reported adverse effects during tirzepatide maintenance treatment, though they typically diminish over time as your body adapts to the medication. The most frequent symptoms include nausea, diarrhoea, constipation, vomiting, and abdominal discomfort. These effects are generally mild to moderate in severity and tend to be most pronounced following dose increases.
To minimise gastrointestinal symptoms during maintenance treatment:
Eat smaller, more frequent meals rather than large portions
Avoid high-fat, greasy, or spicy foods that may exacerbate nausea
Stay well-hydrated, particularly if experiencing vomiting or diarrhoea
Eat slowly and stop when you feel comfortably satisfied
Avoid lying down immediately after eating to reduce reflux symptoms
For persistent nausea, non-pharmacological measures should be tried first. If medication is needed, your GP may recommend anti-emetic medications such as cyclizine, prochlorperazine or ondansetron for short-term use. If constipation becomes problematic, increasing dietary fibre, fluid intake, and physical activity often helps; bulk-forming laxatives may be considered if lifestyle measures are insufficient.
Important contraception advice: Tirzepatide can reduce the effectiveness of oral contraceptives during initiation and dose escalation. If you use oral contraceptives, you should use additional barrier contraception for 4 weeks after starting treatment and for 4 weeks after each dose increase.
More serious but less common side effects require prompt medical attention. Contact your GP or seek urgent care if you experience:
Severe, persistent abdominal pain (potential pancreatitis)
Persistent vomiting or diarrhoea preventing fluid intake (risk of dehydration and acute kidney injury)
Reduced urine output or dark-coloured urine
Signs of gallbladder problems (pain in upper right abdomen, yellowing of skin or eyes)
Symptoms of thyroid tumours (lump in neck, hoarseness, difficulty swallowing)
Severe allergic reactions (rash, itching, swelling, difficulty breathing)
Changes in vision or eye pain
Hypoglycaemia (low blood sugar) is uncommon with tirzepatide alone but may occur if you are taking other diabetes medications concurrently. Symptoms include shakiness, sweating, confusion, and rapid heartbeat. If you have diabetes, discuss blood glucose monitoring and potential medication adjustments with your healthcare team.
While there is no established causal link between tirzepatide and psychiatric effects, some patients report mood changes. If you experience depression, suicidal thoughts, or significant anxiety, contact your healthcare provider promptly.
Tirzepatide should not be used during pregnancy or breastfeeding. If you are planning pregnancy, discuss stopping treatment with your healthcare provider.
If you suspect you are experiencing side effects from tirzepatide, you can report them through the MHRA Yellow Card Scheme (website or app). Regular monitoring and open communication with your medical team throughout maintenance treatment ensure that side effects are managed effectively whilst maximising the therapeutic benefits of tirzepatide for sustained weight loss.
The typical maintenance dose of tirzepatide (Mounjaro) for weight loss is 10 mg or 15 mg once weekly, though some patients achieve satisfactory results on 5 mg weekly. Your healthcare provider will determine your optimal maintenance dose based on weight loss progress, tolerability, and individual treatment goals.
It typically takes 12 to 20 weeks to reach your maintenance dose, depending on your target level. Tirzepatide starts at 2.5 mg weekly and increases every four weeks (2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg), though your doctor may adjust this timeline based on your response and side effects.
Yes, you can remain on a lower maintenance dose such as 5 mg weekly if you achieve clinically meaningful weight loss with acceptable side effects. The optimal maintenance dose is individualised based on your response, tolerability, and treatment goals, not necessarily the highest available dose.
All medical content on this blog is created based on reputable, evidence-based sources and reviewed regularly for accuracy and relevance. While we strive to keep content up to date with the latest research and clinical guidelines, it is intended for general informational purposes only.
DisclaimerThis content is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional with any medical questions or concerns. Use of the information is at your own risk, and we are not responsible for any consequences resulting from its use.
